VPT:CC - Ventripoint to Hold Annual General Meeting of Shareholders on November 1 2023
(TheNewswire)
Toronto, Ontario - TheNewswire -October 23, 2023 - Ventripoint Diagnostics Ltd.(“ Ventripoint ” or the “ Corporation ”) (TSXV:VPT ) ( OTC:VPTDF) will hold its annual general and special meeting ofShareholders (the “AGM”) on Wednesday, November 1, 2023 at 11:00a.m. EST in a virtual-only format conducted via gotomeeting for thefollowing purposes:
-
To receive the audited financial statements of theCorporation;
-
To appoint auditors for the Corporation;
-
To elect each of the directors of the Corporation;and
-
To re-approve and ratify the Corporation’s incentivestock option plan.
Following the AGM, President and CEO, Dr. AlviraMacanovic, will provide a corporate update.
Call in details for the virtual-only AGM are asfollows:
In order to dial into the Meeting within Canada,shareholders and observers will phone +1 (647) 497-9391 and enter theAccess Code noted below.
Outside of Canada, please find your local number:
United States: +1 (646) 749-3129
France: +33 430 001 234
Germany: +49 721 9881 4161
Ireland: +353 16 572 651
Netherlands: +31 207 941 377 Spain: +34 912 71 8491
Sweden: +46 853 527 836
Switzerland: +41 435 5015 61
United Kingdom: +44 330 221 0088
Access Code for Dial In: 923-830-821
Shareholders and observers may also join the Meeting bycomputer, tablet or smartphone by downloading the application athttps://meet.goto.com/install and, once the application is loaded,opening the following link for the meeting:https://meet.goto.com/92383082.
The notice and management information circular and formof proxy for the AGM are available on the Corporation’s website at https://www.ventripoint.com/annual-meeting and under the Corporations profile at www.sedarplus.ca . The Board has fixed September 25, 2023 asthe record date (the "Record Date") for determining theshareholders entitled to receive notice of the annual general meetingor any adjournment or postponement thereof. Holders of record of theCompany's ordinary shares at the close of business on the Record Dateare entitled to attend the annual general meeting and any adjournmentor postponement thereof in person.
Ventripoint’s financial information is available onthe Corporation’s website at
https://www.ventripoint.com/financial .
About Ventripoint DiagnosticsLtd.
Ventripoint has become an industry leader in theapplication of AI (Artificial Intelligence) to echocardiography.Ventripoint's VMS products are powered by its proprietary KBRtechnology, which is the result of a decade of development andprovides accurate volumetric cardiac measurements equivalent to MRI.This affordable, gold-standard alternative allows cardiologistsgreater confidence in the management of their patients. Providingbetter care to patients serves as a springboard and basic standard forall of Ventripoint's products that guide our future developments. Inaddition, VMS+ is versatile and can be used with all ultrasoundsystems from any vendor supported by regulatory market approvals inthe U.S., Europe and Canada.
For further information, please contact:
Jonathan Robinson
416-669-1001
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Copyright (c) 2023 TheNewswire - All rights reserved.